半量替格瑞洛对行冠脉介入治疗的急性冠脉综合征患者的有效性与安全性评价

《半量替格瑞洛对行冠脉介入治疗的急性冠脉综合征患者的有效性与安全性评价》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20153180中国图书分类号R541.4HebeiMedicalUniversity硕士学位论文专业学位半量替格瑞洛对行冠脉介入治疗的急性冠脉综合征患者的有效性与安全性评价研究生：张晓导师：姜云发教授傅向华教授专业：内科学二级学院：河北医科大学第二医院2018年3月目录中文摘要········································································································

2、····1英文摘要············································································································2研究论文半量替格瑞洛对行冠脉介入治疗的急性冠脉综合征患者的有效性与安全性评价前言·······································································································

3、·····4材料与方法································································································5结果············································································································8附图········································

4、····································································9附表··········································································································10讨论················································································

5、··························12结论··········································································································14参考文献··································································································15综述低剂量替格瑞洛在中国急性冠脉综合征

6、患者治疗中的应用进展····17致谢··················································································································26个人简历··········································································································27中文摘要半量替格瑞洛对行冠脉介

7、入治疗的急性冠脉综合征患者的有效性与安全性评价摘要目的：评价半量替格瑞洛对行冠脉介入治疗的急性冠脉综合征（ACS）患者的有效性与安全性。方法：选取明确诊断为ACS并拟行经皮冠状动脉支架置入术（PCI）治疗的患者77例，随机分为半量替格瑞洛组（n=37，替格瑞洛45mg2/日）和标准量替格瑞洛组（n=40，替格瑞洛90mg2/日），两组均给予阿司匹林肠溶片100mg口服1次/日。两组患者入院时基线资料无统计学差异；所有患者均于入院时及术后第3天测定血小板聚集率。观察两组患者住院期间及术后随访1个月主要心血管不良事件（M

8、ACE）、出血、呼吸困难的发生情况。结果：入院时两组患者血小板聚集率（PAR）相比无统计学差异，术后第3天两组PAR分别为25.26%±11.92%、24.40%±11.36%，相比无统计学差异（P＞0.05）。术后TIMI3级血流相比无统计学差异（P＞0.05）。随访过程中半量替格瑞洛组有3人出现心绞痛症状，标准量替格瑞洛组有1人出现心绞痛症